Release
2022/03/11
OSAKA, Japan, March, 11, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that it will donate medicines, primarily those needed for infectious disease treatment, as humanitarian aid to those who have been victims or evacuated in Ukraine. The donated medicines will be provided through the Embassy of Ukraine. Shionogi is also pleased to announce that Shionogi B.V. (its European group company) will donate a total of £100,000 to international support organizations based in the United Kingdom and the Netherlands, including the Red Cross and Save the Children, which are providing humanitarian aid to Ukraine.
Based on the company policy of “Shionogi strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve”, Shionogi seeks to provide medicines required by society as quickly as possible. In addition, the Shionogi group is considering other philanthropic activities to contribute to the health and safety of the victims in Ukraine.
We are deeply concerned about the current situation in Ukraine and sincerely hope that the people of Ukraine can regain a safe and peaceful life as soon as possible.
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
Shionogi website inquiry form: https://www.shionogi.com/global/en/contact.html